# Development of a tool to examine proteomic pathways in the AD brain

> **NIH NIH R41** · PROTEOWISE, INC. · 2020 · $251,944

## Abstract

Abstract
For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations
imposed by the standard techniques for protein analysis. Western blot, the go-to protein
technology of the bench researcher, is no match for the complex brain protein distortions of AD.
To remedy this debility, we devised a technology that we are making available to all researchers
through the company we founded, ProteoWise Inc. ProteoWise is engineering an instrument
that will provide the same protein relative concentration and molecular weight information of
Western blot, 10 x faster, 10 x cheaper, using 10x less sample, and, critically, will provide
unlimited multiplexed proteomic data per sample. To meet the promise of this technology, we
invented micro polyacrylamide electrophoresis (mPAGE), a process we seek to optimize with
the support applied for here. When complete, this instrument will not only make our AD research
more successful, it will empower AD research around the world in our battle against this enemy.

## Key facts

- **NIH application ID:** 10010721
- **Project number:** 1R41AG067855-01
- **Recipient organization:** PROTEOWISE, INC.
- **Principal Investigator:** ERIK C GUNTHER
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $251,944
- **Award type:** 1
- **Project period:** 2020-06-01 → 2020-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10010721

## Citation

> US National Institutes of Health, RePORTER application 10010721, Development of a tool to examine proteomic pathways in the AD brain (1R41AG067855-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10010721. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*